SCHEMBL24045321

SCHEMBL24045321

O=C(CSc1nccn1-c1ccc(Cl)cc1)Nc1cccc(C(F)(F)F)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.89
ALDH1A1 P00352 2/20 0.70
POLB P06746 1/20 0.70
KDM4E B2RXH2 1/20 0.70
MEN1 O00255 1/20 0.64
LMNA P02545 1/20 0.64
KMT2A Q03164 1/20 0.64
SMN1; SMN2 Q16637 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
HSD17B10 Q99714 1/20 0.64
TP53 P04637 1/20 0.61
THRB P10828 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24045352 0.84 MAPT (0.83) MAPTALDH1A1POLBMEN1LMNA
SCHEMBL24045100 0.82 MAPK1 (0.75) MAPTPOLBTP53
SCHEMBL26687689 0.80 MAPT (0.83) MAPTALDH1A1POLBMEN1LMNA
SCHEMBL24045322 0.79 MAPT (0.75) MAPTALDH1A1POLBMEN1LMNA
SCHEMBL26687676 0.79 MAPT (0.75) MAPTALDH1A1POLBMEN1LMNA
SCHEMBL24045260 0.79 MAPT (0.75) MAPTALDH1A1POLBMEN1LMNA
SCHEMBL24045329 0.78 TP53 (0.81) MAPTALDH1A1POLBMEN1LMNA
SCHEMBL24045325 0.78 MAPT (0.82) MAPTPOLBLMNATP53
SCHEMBL24045102 0.77 MAPT (0.84) MAPTALDH1A1POLBMEN1LMNA
SCHEMBL24045326 0.77 MAPT (0.87) MAPTALDH1A1LMNASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339878-A1 SLC26A3 INHIBITORS AND USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-10-26 US disclosed
US-11591304-B2 SLC26A3 inhibitors and use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-28 US disclosed
US-20210363123-A1 SLC26A3 INHIBITORS AND USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339878-A1 SLC26A3 INHIBITORS AND USE THEREOF SLC26A3, SLC10A2, SLC10A6 MAPT 2923/4885ALDH1A1 2345/4885POLB 1871/4885
US-20210363123-A1 SLC26A3 INHIBITORS AND USE THEREOF SLC26A3, SLC10A2, SLC10A6 MAPT 3087/4885ALDH1A1 2687/4885POLB 2167/4885
US-11591304-B2 SLC26A3 inhibitors and use thereof SLC26A3, SLC10A2, SLC10A6 MAPT 3087/4885ALDH1A1 2687/4885POLB 2167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.